The Collapse of IPR—And Here’s What Founders Need to Know

Why It Matters

The procedural shift dramatically lowers the likelihood of IPR‑driven invalidation, making patents a more reliable asset for fundraising, licensing, and litigation strategy.

Key Takeaways

• IPR institution rate fell from 65% to 37% by Feb 2026
• Ex‑parte reexamination filings hit 198 in Q3 2025, a record
• April 2026 USPTO rule adds 30‑day pre‑order response for EPR
• Founders must prepare 30‑page responses within non‑extendable deadline
• Strong, core‑innovation patents now more valuable than procedural shields

Pulse Analysis

The abrupt collapse of IPR institution rates reflects a strategic pivot by the USPTO to manage PTAB workload and curb perceived abuse by non‑practicing entities. By inserting a discretionary denial gate, the agency reduced the success odds for challengers, prompting a mass migration to ex‑parte reexamination, which historically enjoys a 95% grant rate. This shift not only altered the volume of post‑grant disputes but also signaled a broader policy trend: the USPTO is favoring mechanisms that preserve issued patents while still providing a pathway for legitimate prior‑art challenges.

April 2026’s emergency pre‑order procedure further tilts the balance toward patent owners. The 30‑day, 30‑page response window forces challengers to prove a substantial new question of patentability (SNQ) before the USPTO can proceed, effectively giving owners a final defensive argument on the record. Because the deadline is non‑extendable, firms must act quickly, securing counsel and expert testimony ahead of any EPR notice. The rule also limits the challenger’s ability to re‑file the same arguments, curbing the serial challenge model that once dominated the post‑grant landscape.

For founders, the new regime translates into tangible strategic advantages. A well‑crafted portfolio that protects core innovations and aligns with product roadmaps can now be leveraged for higher valuations, investor confidence, and stronger licensing positions. However, the procedural shield is not a substitute for substantive patent quality; narrow or peripheral claims remain vulnerable. Companies should audit their patents, prioritize broad, enforceable claims, and allocate budget for rapid pre‑order responses—typically $40‑$90 k depending on complexity—to avoid costly SNQ proceedings. In an environment where jury awards exceed $4 billion annually, robust patents have become a decisive competitive moat.